Trial Profile
A Phase 1/2 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Balstilimab (Primary) ; Botensilimab (Primary)
- Indications Cervical cancer; Colorectal cancer; Endometrial cancer; Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Sarcoma; Solid tumours
- Focus Adverse reactions
- Sponsors Agenus
- 12 Apr 2024 According to an Agenus media release, Pending planned meetings with the FDA, Agenus plans to submit a Biologics License Application (BLA) for BOT/BAL in refractory MSS CRC later this year and plans to present Phase 1 survival data, at a major medical conference in the second half of 2024.
- 12 Apr 2024 Results (at the data cutoff of March 1, 2024, n=77) presented in the Agenus Media Release.
- 08 Nov 2023 Planned End Date changed from 1 Dec 2024 to 1 Dec 2026.